Microbrush reported on Wednesday the immediate availability of the US FDA-listed, ready-for-use, sterilized, nasopharyngeal test swab to meet the growing demand for COVID-19 testing requirements.
Manufactured in Grafton, Wisconsin, Microbrush's test swab from soft nylon fibers provides an improved patient experience over 3D-printed swabs. The swabs are individually packaged in a medical-grade pouch and are intended for clinical nasopharyngeal sample collection.
Microbrush is a subsidiary of Young Innovations Inc, a provider of equipment used by dentists, hygienists, dental assistants and consumers.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval